Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
- 15 September 2020
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 84 (4), 1000-1009
- https://doi.org/10.1016/j.jaad.2020.08.127
Abstract
No abstract availableFunding Information
- Regeneron Pharmaceuticals
This publication has 28 references indexed in Scilit:
- Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registryJournal of the American Academy of Dermatology, 2020
- Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort studyJournal of the American Academy of Dermatology, 2020
- Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyJournal of the American Academy of Dermatology, 2020
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical TrialJAMA Dermatology, 2020
- Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registryAllergy, 2019
- Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice dataBritish Journal of Dermatology, 2019
- Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohortJournal of the American Academy of Dermatology, 2019
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)British Journal of Dermatology, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisThe New England Journal of Medicine, 2016